Table 1. Main characteristics of included studies.
| Study or Subgroup | Country | Histology | Intervention Group | Control Group | Overall Survival | Metastasis/Recurrence | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Size | Type | Dose (mg/m2) | Size | Type | Follow-up (mo) | HR and 95%Cl | Intervention | Control | |||
| Law et al., 1997 | China | SCC | 74 | CT+S | C:100 d1; F:500 d1-5 | 73 | S | 17 | 0.73 (0.53, 1.00) | 12/29 | 19/50 |
| Ancona et al., 2001 | Italy | SCC | 47 | CT+S | C:100 d1; F:500 d1-5 | 47 | S | 24 | 0.84 (0.58, 1.10) | 19/28 | 19/29 |
| Kelsen et al., 2007 | USA | SCC&AC | 216 | CT+S | C:100 d1; F:1000 d1-5 | 227 | S | 56 | 1.07 (0.87, 1.32) | NR | NR |
| Allum et al., 2009 | UK | SCC | 400 | CT+S | C:100 d1; F:1000 d1-5 | 402 | S | 37 | 0.84 (0.72, 0.98) | 68/82 | 60/101 |
| Boonstra et al., 2011 | Netherland | SCC | 85 | CT+S | C:80 d1; Eto:100 d1,2 | 84 | S | 60 | 0.71 (0.51, 0.98) | 14/25 | 15/31 |
| Ando et al., 2012 | Japan | SCC | 164 | CT+S | C:80 d1; F:800 d1-5 | 166 | S | 62 | 0.64 (0.45, 0.91) | NR/51 | NR/41 |
| Maipang et al., 1994 | Thailand | SCC | 24 | CT+S | C:100 d1; Vinblastine:3 d1-4; B:10 d1-5 | 22 | S | 17 | 1.61 (0.79, 3.27) | NR | NR |
| Nygaard et al., 1992* | Norway | SCC | 50 | CT+S | C:20 d1-5; B:10mg, d1-5 | 41 | S | 18 | 1.10 (0.93, 1.30) | NR | NR |
| Nygaard et al., 1992* | Norway | SCC | 47 | CRT+S | C:20 d1-5; B:10mg, d1-5; 35GY | 41 | S | 18 | 0.76 (0.45, 1.28) | NR | NR |
| Nygaard et al., 1992* | Norway | SCC | 48 | RT+S | 35Gy | 41 | S | 18 | 0.80 (0.63, 1.02) | NR | NR |
| Schlag et al., 1992 | German | SCC | 22 | CT+S | C:20 d1-5;F:1000, d1-d5 | 24 | S | 75 | 0.97 (0.60, 1.57) | NR | NR |
| Ychou et al., 2011 | France | AC, GEJ | 113 | CT+S | C:100 d1; F:800, d1-5 | 111 | S | 60 | 0.69 (0.50, 0.95) | 49/63 | 62/71 |
| Pouliquen et al., 1996 | France | SCC | 52 | CT+S | C:100, d1; F:20, d1-5 | 68 | S | NR | 1.03 (0.89, 1.13) | NR | NR |
| Ando et al., 1997 | Japan | SCC | 105 | CT+S | C:70 d1,21; V: 3 d1.21 | 100 | S | 59.2 | 1.08 (0.87, 1.34) | NR/57 | NR/55 |
| Ando et al., 2003 | Japan | SCC | 120 | CT+S | C:80 d1; F:800, d1-5 | 122 | S | NR | 1.20 (0.96, 1.51) | NR/63 | NR/45 |
| Lee et al., 2005 | Korea | SCC | 40 | CT+S | C:60 d1-4; F:1000, d1-3 | 52 | S | 25 | 0.60 (0.47, 0.77) | 18/28 | 9/19 |
| Heroor et al., 2003 | Japan | SCC | 94 | CT+S | C:70 d1; F:700, d1-4, V 3, d1 | 117 | S | 80 | 1.46 (1.21, 1.71) | NR | NR |
| Shiozaki et al., 2004 | Japan | SCC | 98 | CT+S | C:10, d1-5; F250-500, d1-5 | 52 | S | NR | 0.48 (0.35, 0.66) | NR | NR |
| Zhang et al., 2008 | China | SCC&AC | 66 | CT+S | C:25, d1-3; F:375, d1-5; L:135 d1-5 | 160 | S | NR | 1.36 (0.93, 1.98) | NR | NR |
| Walsh et al., 1996 | Ireland | AC | 55 | CRT+S | C:75; F:15mg/kg/d; 45Gy | 55 | S | 10 | 0.53 (0.33, 0.84) | NR | NR |
| Urba et al., 2001 | USA | SCC&AC | 47 | CRT+S | C:20; F:300; 35Gy | 50 | S | 98 | 0.75 (0.46, 1.22) | NR | NR |
| Stahl et al., 2009 | German | SCC | 60 | CRT+S | C:50; Eto:80; 30Gy | 59 | CT++S | 45.6 | 0.67 (0.41, 1.09) | NR/19 | NR/27 |
| Burmeister et al., 2011 | Australia | AC | 39 | CRT+S | C:80; F:1000 /d; 35Gy | 36 | CT#+S | 65 | 0.79 (0.41, 1.54) | NR/18 | NR/21 |
| Tepper et al., 2008 | USA | SCC&AC | 30 | CRT+S | C:100; F:1000; 41.5Gy | 26 | S | 60 | 0.51 (0.38, 0.68) | NR/9 | NR/12 |
| van Hagen et al., 2012 | Netherlands | SCC&AC | 178 | CRT+S | Carboplatin:2mg/ ml/min; P:50 ;41.4Gy | 188 | S | 45.4 | 0.73 (0.54, 1.00) | NR/62 | NR/188 |
| Burmeister et al., 2005 | Australia | SCC&AC | 128 | CRT+S | C:80; F:1800; 35Gy | 128 | S | 65 | 0.89 (0.67, 1.19) | 48/61 | 54/68 |
| Lv et al., 2010** | China | SCC | 80 | CRT+S | P:135 d1,22; C 20 d1-3 and 22-25; 40Gy | 80 | S | 45 | 0.71 (0.60, 0.85) | NR | NR |
| Lv et al., 2010** | China | SCC | 78 | CRT+S | P:135 d1,22; C 20 d1-3 and 22-25; 40Gy | 80 | S | 45 | 0.68 (0.58, 0.82) | NR | NR |
| Apinop et al., 1994 | Thailand | SCC | 35 | CRT+S | C 100 d1,22; F: 1000 d1-4and22-25; 40Gy | 34 | S | NR | 0.80 (0.48, 1.34) | NR | NR |
| Le Prise et al., 1994 | France | SCC | 41 | CRT+S | C 100 d1,22; F: 600 d1-4and22-25; 20Gy | 45 | S | 16 | 0.85 (0.50, 1.46) | 8/17 | 10/17 |
| Walsh et al., 1995 | Ireland | AC | 58 | CRT+S | C:75; F:15mg/kg/d; 45Gy | 55 | S | 10 | 0.58 (0.38, 0.88) | NR | NR |
| Mariette et al., 2014 | France | SCC | 98 | CRT+S | C 75 d1; F:800 on d1-4; 45Gy | 97 | S | 93.6 | 0.99 (0.69, 1.40) | 22/28 | 28/43 |
| Kobayashi et al., 2000 | Japan | NR | 91 | CT+S | F:600 | 80 | S | NR | 1.10 (0.67, 1.81) | NR | NR |
| Launois et al., 1981 | France | SCC | 67 | RT+S | 64-90Gy preop | 57 | S | NR | 1.17 (1.04, 1.32) | NR | NR |
| Gignoux et al., 1987 | Europe | SCC | 115 | RT+S | 33 Gy preop | 114 | S | 43.2 | 1.12 (0.95, 1.32) | NR | NR |
| Arnott et al., 1992 | Scotland | SCC | 90 | RT+S | 20 Gy Preop | 86 | S | NR | 1.02 (0.87, 1.19) | NR | NR |
| Lee et al., 2004 | Korea | SCC | 51 | CRT+S | C:60; F:1000; 45.6Gy | 50 | S | 25 | 0.88 (0.48, 1.62) | 6/19 | 12/18 |
Intervention: NR-not report C - Cisplatin, F-Fluorouracil, Eto-Etoposide, B-Bleomycin, V-Vindesine, P-Paclitaxel; Treatment: CRT-chemoradiotherapy, S-surgery, CT-chemotherapy, RT-radiotherapy; Tumor: SCC-Squamous Cell Carcinoma, AC-Adenocarcinoma, GEJ-Gastroesophageal Junction; CI-Confidence Interval; HR-Hazard Ratio
Note:*: These three studies are from the same paper. **: These two studies are from the same paper. The first one is the preoperative group and the latter one is the postoperative group. +: The dose is F: 2000mg/m2, leucovorin: 500mg/m2, C: 50mg/m2; #: The dose is C:80mg/m2, F:1000mg/m2.